A lipoprotein lipase-promoting agent, NO-1886, improves glucose and lipid metabolism in high fat, high sucrose-fed New Zealand white rabbits

Experimental Diabesity Research

Volumn 4, Issue 1, 2003, Pages 27-34

  Yin, Weidong ^a,b   Yuan, Zhonghua ^b   Tsutsumi, Kazuhiko ^c   Xie, Yuxiang ^b   Zhang, Qiuju ^b   Wang, Zongbao ^b   Fu, Guoxiang ^b   Long, Guang ^b   Yang, Yongzong ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Medicial School NanHua University   (China)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CAS 133208 93 2; Diabetes; Free fatty acids; Glucose; Insulin resistance; NO 1886; Rabbits; Triglycerides

Indexed keywords

4 [(4 BROMO 2 CYANOPHENYL)CARBAMOYL]BENZYLPHOSPHONIC ACID DIETHYL ESTER; ENZYME ACTIVATOR; FAT; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; SUCROSE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL FOOD; ARTICLE; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVATION; FAT INTAKE; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; GLUCOSE METABOLISM; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID METABOLISM; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RABBIT; SUGAR INTAKE; TRIACYLGLYCEROL BLOOD LEVEL;

ABDOMEN; ADIPOSE TISSUE; ANIMALS; ANTILIPEMIC AGENTS; BENZAMIDES; BLOOD GLUCOSE; DIETARY FATS; DIETARY SUCROSE; ENZYME ACTIVATION; LIPOPROTEIN LIPASE; MALE; MODELS, ANIMAL; ORGANOPHOSPHORUS COMPOUNDS; RABBITS; TIME FACTORS;

EID: 0042922737     PISSN: 15438600     EISSN: None     Source Type: Journal    
DOI: 10.1080/15438600303732     Document Type: Article

References (19)

1. Sivitz, W. I. (2001) Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression. Postgrad. Med., 109, 55-59.
2. Groop, L. (2000) Pathogenesis of type 2 diabetes: The relative contribution of insulin resistance and impaired insulin secretion. Int. J. Clin. Pract. Suppl., 113, 3-13.
3. Leibowitz, G., Yuli, M., Donath, M. Y., et al. (2001) Beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. Diabetes, 50(Suppl 1), S113-S 117.
4. Jörns, A., Tiedge, M., Ziv, E., Shafrir, E., and Lenzen, S. (2002) Gradual loss of pancreatic beta-cell insulin, glucokinase and GLUT2 glucose transporter immunoreactivities during the time course of nutritionally induced type-2 diabetes in Psammomys obesus (sand rat). Virchows Arch., 440, 63-69.
5. Porte, D. (1999) Mechanisms for hyperglycemia in the metabolic syndrome: The key role of β-cell dysfunction. Ann. N.Y. Acad. Sci., 892, 73-83.
6. Thresher, J. S., Podolin, D. A., Wei, Y., Mazzeo, R. S., Pagliassotti, M. J. (2000) Comparison of the effects of sucrose and fructose on insulin action and glucose tolerance. Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R1334-R1340.
7. Yin, W., Tsutsumi, K., Yuan, Z., and Yang, B. (2002) A lipoprotein lipase activator NO-1886 suppresses atherosclerosis in aorta of mild diabetic rabbits. Arzneimittel. Forschung. Drug Res., 52, 610-614.
8. Yin, W., Yuan, Z., and Yang, B. (2002) A diet high in saturated fat and sucrose alters glucoregulation, and induces aortic fatty streaks in New Zealand White rabbits. Int. J. Exp. Diabetes Res., 3, 179-184.
9. Tsutsumi, K., Inoue, Y., Shima, A., et al. (1993) The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long-term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J. Clin. Invest., 92, 411-417.
10. Chiba, T., Miura, S., Sawamura, F., et al. (1997) Antiatherogenic effects of a novel lipoprotein lipase-enhancing agent in cholesterol-fed New Zealand White rabbits. Arterioseler. Thromb. Vasc. Biol., 17, 2601-2608.
11. Hara, T., Kusunoki, M., Tsutsumi, K., et al. (1998) A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging. Eur. J. Pharmacol., 350, 75-79.
12. Kusunoki, M., Hara, T., Tsutsumi, K., et al. (2000) The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia, 43, 875-880.
13. Tsutsumi, K., Inoue, Y., Shima, A., et al. (1995) Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes, 44, 414-417.
14. Tsutsumi, K., Inoue, Y., and Murase, T. (2000) Effects of NO-1886, a lipoprotein lipase promoting agent on homozygous and heterozygous WHHL rabbits. Arzneim. Forsch., 50, 118-121.
15. Hara, T., Cameron-Smith, D., Cooney, G. J., et al. (1998) The action of novel lipoprotein lipase activator, NO-1886, in hypertriglyceridemic fructose-fed rats. Metabolism, 47, 149-153.
16. Ginsberg, H. N. (1996) Diabetic dyslipidemia: Basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes, 45(Suppl 3), S27-S30.
17. Garg, A. (1998) Treatment of diabetic dyslipidemia. Am. J. Cardiol., 81, 47B-51B.
18. Taskinen, M. R. (2001) Pathogenesis of dyslipidemia in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes, 109(Suppl 2), S180-S188.
19. Taskinen, M. R. (2002) Diabetic dyslipidemia. Atheroscler. Suppl., 3, 47-51.